tirzepatide/methylcobalamin/nad+ Troubling Findings in Study of GLP-1 Compounders NAD+ | GoodGirlRx

Clinicians should maintain awareness that correlation does not imply causation

Employment status also influences treatment adherence, as research shows employed individuals demonstrate higher completion rates

Retatrutide: A triple-agonist (GLP-1/GIP/glucagon) that targets multiple metabolic pathways and has shown impressive weight loss results in studies

"Lifestyle changes are always the hallmark of how we intervene first, and we teach people about how to eat healthy and also how to move and exercise, but for some people, it's not enough," she said

Individuals who were 21 years of age or older, were at moderate risk for cardiovascular disease, and had a newly filled prescription for SGLT2i, GLP1RA, DPP4i, or SU between January 1, 2014, and December 31, 2021 were considered for the analysis